Manus Bio, Inc.
Manus Bio Inc. is a leading bioalternatives scale-up platform dedicated to accelerating the commercialization of biologically produced alternatives across food ingredients, agricultural inputs, and industrial materials. The company leverages advanced fermentation technology and synthetic biology to produce sustainable, cost-effective, and reliable natural products, reducing dependence on finite resources and supporting supply chain resilience. Manus collaborates with industry leaders, develops innovative bio-based solutions, and contributes to the growth of the bioeconomy, with a focus on environmental sustainability and market readiness.
Industries
Nr. of Employees
medium (51-250)
Manus Bio, Inc.
Manus Bio Inc., 123 Bio Lane, Cambridge, MA 02139
Patents
Production of steviol glycosides through whole cell biotransformation of steviol glycoside intermediates
US-12012626-B2
View Details
Production of steviol glycosides through whole cell biotransformation of steviol glycoside intermediates
US-12012626-B2
View DetailsProducts
Fermentation-derived citrus flavor ingredient (nootkatone)
A fermentation-produced citrus flavor compound formulated to match natural citrus extracts, produced without agricultural citrus inputs and designed for consistent sensory profile and lower greenhouse gas intensity than plant-derived sources.
Fermentation-derived sweetener ingredients (steviol glycoside analogs)
Microbially produced sweetener molecules that replicate plant-derived sweetener chemistry to provide stable supply and improved cost and sensory outcomes versus traditional extraction.
Environmentally friendly acaricide/tick repellent ingredient
A plant-derived acaricidal compound reproduced via fermentation to enable scalable production for topical consumer products that repel and incapacitate ticks and other insects.
Fermentation-derived artemisinin precursor and semi-synthetic artemisinin production
Production of an artemisinin precursor via fermentation combined with continuous-flow chemical conversion to produce artemisinin and derivatives at scale for antimalarial therapies.
Fermentation-derived citrus flavor ingredient (nootkatone)
A fermentation-produced citrus flavor compound formulated to match natural citrus extracts, produced without agricultural citrus inputs and designed for consistent sensory profile and lower greenhouse gas intensity than plant-derived sources.
Fermentation-derived sweetener ingredients (steviol glycoside analogs)
Microbially produced sweetener molecules that replicate plant-derived sweetener chemistry to provide stable supply and improved cost and sensory outcomes versus traditional extraction.
Environmentally friendly acaricide/tick repellent ingredient
A plant-derived acaricidal compound reproduced via fermentation to enable scalable production for topical consumer products that repel and incapacitate ticks and other insects.
Fermentation-derived artemisinin precursor and semi-synthetic artemisinin production
Production of an artemisinin precursor via fermentation combined with continuous-flow chemical conversion to produce artemisinin and derivatives at scale for antimalarial therapies.
Services
Structured programs providing end-to-end support from pathway and strain development through piloting and commercial manufacturing to accelerate partner products to market.
On-site, cGMP-capable production services for pharmaceutical intermediates, APIs and high-volume bio-based ingredients integrating fermentation and chemical conversion routes.
Analytical testing, specification development and QA workflows to support product characterization, batch release and regulatory submissions for bio-based molecules.
Co-development and commercialization services that coordinate technical development, supply agreements and commercialization plans with ingredient formulators and commercial partners.
Structured programs providing end-to-end support from pathway and strain development through piloting and commercial manufacturing to accelerate partner products to market.
On-site, cGMP-capable production services for pharmaceutical intermediates, APIs and high-volume bio-based ingredients integrating fermentation and chemical conversion routes.
Analytical testing, specification development and QA workflows to support product characterization, batch release and regulatory submissions for bio-based molecules.
Co-development and commercialization services that coordinate technical development, supply agreements and commercialization plans with ingredient formulators and commercial partners.
Expertise Areas
- Cell factory and metabolic engineering
- Enzyme engineering and biochemical characterization
- High-throughput automation and screening
- Fermentation scale-up and large-scale biomanufacturing
Key Technologies
- Precision fermentation (pilot to multi-10k L)
- Microbial genome engineering and high-throughput strain construction
- Computational protein design
- Lipid nanodisc and membrane protein assay platforms
News & Updates
A coalition to accelerate U.S. capabilities in scalable, secure biomanufacturing.
A strategic merger leveraging end-to-end platform and domestic manufacturing to accelerate bioalternative commercialization.
Calls for coordinated federal action to accelerate U.S. bioeconomy leadership.
A sustainable, clean-label citrus ingredient with a winning taste profile, supporting market demand for natural flavors.
Funding to support domestic production of critical medicines, including anti-malaria therapies, reducing reliance on foreign sources.
Funding from the Bill & Melinda Gates Foundation to develop scalable, cost-effective production of artemisinin, a key malaria treatment.
A coalition to accelerate U.S. capabilities in scalable, secure biomanufacturing.
A strategic merger leveraging end-to-end platform and domestic manufacturing to accelerate bioalternative commercialization.
Calls for coordinated federal action to accelerate U.S. bioeconomy leadership.
A sustainable, clean-label citrus ingredient with a winning taste profile, supporting market demand for natural flavors.
Funding to support domestic production of critical medicines, including anti-malaria therapies, reducing reliance on foreign sources.
Funding from the Bill & Melinda Gates Foundation to develop scalable, cost-effective production of artemisinin, a key malaria treatment.